Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

The SmartOne.ai team generates hyper-realistic document structures, complete with authentic fonts, handwriting ... Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 ...

In blue font are the molecules we’ve already developed ... leveraging either multi specific T cell engagers or ADC therapeutic modalities to build a diverse and derisk portfolio.

The Albuquerque Isotopes revealed its newest alternate identity. The ‘City Roots’ series ties in the history and culture of ...

The overall readout is in line with the Chinese data that drummed up excitement in the antibody-drug conjugate (ADC) last year, but investors sent Corbus’ stock down 10% in premarket trading.

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...

Union Cooperation Minister Amit Shah praised the progress of cooperatives under Prime Minister Narendra Modi's leadership, ...

According to a recently published report from Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, the Network ...

The phase 1b trial is investigating the ADC and Keytruda – with or without chemo – in both previously-untreated and pretreated patients with advanced NSCLC who don’t have genetic mutations ...

Introduce a different font, a fresh colour, or a new shape, and suddenly customers who never gave the original packaging much thought become deeply invested in its preservation. And yet ...

For the convenience of reading this table in a larger font, the table below is available as a PDF as well. Dividend yield is an important component of a REIT's total return. The particularly high ...